Literature DB >> 29716753

Anal and rectal function after intensity-modulated prostate radiotherapy with endorectal balloon.

Robin Krol1, Gill M McColl2, Wim P M Hopman3, Robert J Smeenk2.   

Abstract

BACKGROUND AND
PURPOSE: Late anorectal toxicity influences quality of life after external beam radiotherapy (EBRT) for prostate cancer. A daily inserted endorectal balloon (ERB) during EBRT aims to reduce anorectal toxicity. Our goal is to objectify anorectal function over time after prostate intensity-modulated radiotherapy (IMRT) with ERB.
MATERIAL AND METHODS: Sixty men, irradiated with IMRT and an ERB, underwent barostat measurements and anorectal manometry prior to EBRT and 6 months, one year and 2 years after radiotherapy. Primary outcome measures were rectal distensibility and rectal sensibility in response to stepwise isobaric distensions and anal pressures.
RESULTS: Forty-eight men completed all measurements. EBRT reduced maximal rectal capacity 2 years after EBRT (250 ± 10 mL vs. 211 ± 10 mL; p < 0.001), area under the pressure-volume curve (2878 ± 270 mL mmHg vs. 2521 ± 305 mL mmHg; p = 0.043) and rectal compliance (NS). Sensory pressure thresholds for first sense and first urge (both p < 0.01) increased. Anal maximum pressure diminished after IMRT (p = 0.006).
CONCLUSIONS: Rectal capacity and sensory function are increasingly affected over time after radiotherapy. There is an indication that these reductions are affected less with IMRT + ERB compared to conventional radiation techniques.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Electronic barostat; External beam radiotherapy; Intensity modulated radiotherapy; Localized prostate cancer; Manometry; Rectal distension

Mesh:

Year:  2018        PMID: 29716753     DOI: 10.1016/j.radonc.2018.03.032

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

Review 1.  Prostatic irradiation-induced sexual dysfunction: a review and multidisciplinary guide to management in the radical radiotherapy era (Part I defining the organ at risk for sexual toxicities).

Authors:  Marigdalia K Ramirez-Fort; Marc J Rogers; Roberto Santiago; Sean S Mahase; Melissa Mendez; Yi Zheng; Xiang Kong; James A Kashanian; M Junaid Niaz; Shearwood McClelland; Xiaodong Wu; Neil H Bander; Peter Schlegel; John P Mulhall; Christopher S Lange
Journal:  Rep Pract Oncol Radiother       Date:  2020-03-19

Review 2.  Effectiveness of rectal displacement devices in managing prostate motion: a systematic review.

Authors:  Mahdieh Afkhami Ardekani; Hamed Ghaffari; Mahmoud Navaser; Seyed Hamid Zoljalali Moghaddam; Soheila Refahi
Journal:  Strahlenther Onkol       Date:  2020-05-22       Impact factor: 3.621

3.  Dose-volume analysis of predictors for acute anal toxicity after radiotherapy in prostate cancer patients.

Authors:  Xingsi Peng; Sha Zhou; Shiliang Liu; Jibin Li; Sijuan Huang; Xiaobo Jiang; Maosheng Lin; Shaomin Huang; Chengguang Lin; Chaonan Qian; Mengzhong Liu; Liru He
Journal:  Radiat Oncol       Date:  2019-10-10       Impact factor: 3.481

4.  Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results.

Authors:  Thomas Zilli; Sandra Jorcano; Samuel Bral; Carmen Rubio; Anna M E Bruynzeel; Angelo Oliveira; Ufuk Abacioglu; Heikki Minn; Zvi Symon; Raymond Miralbell
Journal:  Cancer Med       Date:  2020-03-11       Impact factor: 4.452

5.  In vivo dosimetry with an electronic portal imaging device for prostate cancer radiotherapy with an endorectal balloon.

Authors:  Bo Sterckx; Isabell Steinseifer; Markus Wendling
Journal:  Phys Imaging Radiat Oncol       Date:  2019-11-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.